Hypertrophic cardiomyopathy: genetics and clinical perspectives

被引:64
作者
Wolf, Cordula Maria [1 ]
机构
[1] Tech Univ Munich, German Heart Ctr Munich, Dept Pediat Cardiol & Congenital Heart Dis, Lazarettstr 36, D-80636 Munich, Germany
关键词
Hypertrophic cardiomyopathy (HCM); molecular genetics; pathogenesis; clinical management; sudden cardiac death; SUDDEN CARDIAC DEATH; CARDIOVASCULAR MAGNETIC-RESONANCE; LEFT-VENTRICULAR HYPERTROPHY; OUTFLOW TRACT OBSTRUCTION; MYOSIN HEAVY-CHAIN; SARCOMERE MUTATION CARRIERS; AMERICAN-HEART-ASSOCIATION; ALPHA ENZYME REPLACEMENT; SURGICAL SEPTAL MYECTOMY; CARDIOLOGY WORKING GROUP;
D O I
10.21037/cdt.2019.02.01
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and defined by unexplained isolated progressive myocardial hypertrophy, systolic and diastolic ventricular dysfunction, arrhythmias, sudden cardiac death and histopathologic changes, such as myocyte disarray and myocardial fibrosis. Mutations in genes encoding for proteins of the contractile apparatus of the cardiomyocyte, such as beta-myosin heavy chain and myosin binding protein C, have been identified as cause of the disease. Disease is caused by altered biophysical properties of the cardiomyocyte, disturbed calcium handling, and abnormal cellular metabolism. Mutations in sarcomere genes can also activate other signaling pathways via transcriptional activation and can influence non-cardiac cells, such as fibroblasts. Additional environmental, genetic and epigenetic factors result in heterogeneous disease expression. The clinical course of the disease varies greatly with some patients presenting during childhood while others remain asymptomatic until late in life. Patients can present with either heart failure symptoms or the first symptom can be sudden death due to malignant ventricular arrhythmias. The morphological and pathological heterogeneity results in prognosis uncertainty and makes patient management challenging. Current standard therapeutic measures include the prevention of sudden death by prohibition of competitive sport participation and the implantation of cardioverter-defibrillators if indicated, as well as symptomatic heart failure therapies or cardiac transplantation. There exists no causal therapy for this monogenic autosomal-dominant inherited disorder, so that the focus of current management is on early identification of asymptomatic patients at risk through molecular diagnostic and clinical cascade screening of family members, optimal sudden death risk stratification, and timely initiation of preventative therapies to avoid disease progression to the irreversible adverse myocardial remodeling stage. Genetic diagnosis allowing identification of asymptomatic affected patients prior to clinical disease onset, new imaging technologies, and the establishment of international guidelines have optimized treatment and sudden death risk stratification lowering mortality dramatically within the last decade. However, a thorough understanding of underlying disease pathogenesis, regular clinical follow-up, family counseling, and preventative treatment is required to minimize morbidity and mortality of affected patients. This review summarizes current knowledge about molecular genetics and pathogenesis of HCM secondary to mutations in the sarcomere and provides an overview about current evidence and guidelines in clinical patient management. The overview will focus on clinical staging based on disease mechanism allowing timely initiation of preventative measures. An outlook about so far experimental treatments and potential for future therapies will be provided.
引用
收藏
页码:S388 / S415
页数:28
相关论文
共 251 条
  • [1] How to develop a clinic for sudden cardiac arrest survivors and families of non-survivors
    Abrams, Dominic J.
    [J]. CARDIOLOGY IN THE YOUNG, 2017, 27 : S3 - S9
  • [2] Ackerman MJ, 2011, HEART RHYTHM, V8, P1308, DOI [10.1016/j.hrthm.2011.05.020, 10.1093/europace/eur245]
  • [3] Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy on relation to delayed enhancement on cardiovascular magnetic resonance
    Adabag, A. Selcuk
    Maron, Barry J.
    Appelbaum, Evan
    Harrigan, Caltlin J.
    Buros, Jacqueline L.
    Gibson, C. Michael
    Lesser, John R.
    Hanna, Constance A.
    Udelson, James E.
    Manning, Warren J.
    Maron, Martin S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) : 1369 - 1374
  • [4] Myectomy with mitral valve repair versus replacement in adult patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis
    Afanasyev, Alexander
    Bogachev-Prokophiev, Alexander
    Lenko, Eugeniy
    Sharifulin, Ravil
    Ovcharov, Michael
    Kozmin, Dmitriy
    Karaskov, Alexander
    [J]. INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2019, 28 (03) : 465 - 472
  • [5] Molecular targets and regulators of cardiac hypertrophy
    Agrawal, Rohini
    Agrawal, Neeraj
    Koyani, Chintan N.
    Singh, Randhir
    [J]. PHARMACOLOGICAL RESEARCH, 2010, 61 (04) : 269 - 280
  • [6] A global reference for human genetic variation
    Altshuler, David M.
    Durbin, Richard M.
    Abecasis, Goncalo R.
    Bentley, David R.
    Chakravarti, Aravinda
    Clark, Andrew G.
    Donnelly, Peter
    Eichler, Evan E.
    Flicek, Paul
    Gabriel, Stacey B.
    Gibbs, Richard A.
    Green, Eric D.
    Hurles, Matthew E.
    Knoppers, Bartha M.
    Korbel, Jan O.
    Lander, Eric S.
    Lee, Charles
    Lehrach, Hans
    Mardis, Elaine R.
    Marth, Gabor T.
    McVean, Gil A.
    Nickerson, Deborah A.
    Wang, Jun
    Wilson, Richard K.
    Boerwinkle, Eric
    Doddapaneni, Harsha
    Han, Yi
    Korchina, Viktoriya
    Kovar, Christie
    Lee, Sandra
    Muzny, Donna
    Reid, Jeffrey G.
    Zhu, Yiming
    Chang, Yuqi
    Feng, Qiang
    Fang, Xiaodong
    Guo, Xiaosen
    Jian, Min
    Jiang, Hui
    Jin, Xin
    Lan, Tianming
    Li, Guoqing
    Li, Jingxiang
    Li, Yingrui
    Liu, Shengmao
    Liu, Xiao
    Lu, Yao
    Ma, Xuedi
    Tang, Meifang
    Wang, Bo
    [J]. NATURE, 2015, 526 (7571) : 68 - +
  • [7] The functions of animal microRNAs
    Ambros, V
    [J]. NATURE, 2004, 431 (7006) : 350 - 355
  • [8] Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium
    Amendola, Laura M.
    Jarvik, Gail P.
    Leo, Michael C.
    McLaughlin, Heather M.
    Akkari, Yassmine
    Amaral, Michelle D.
    Berg, Jonathan S.
    Biswas, Sawona
    Bowling, Kevin M.
    Conlin, Laura K.
    Cooper, Greg M.
    Dorschner, Michael O.
    Dulik, Matthew C.
    Ghazani, Arezou A.
    Ghosh, Rajarshi
    Green, Robert C.
    Hart, Ragan
    Horton, Carrie
    Johnston, Jennifer J.
    Lebo, Matthew S.
    Milosavljevic, Aleksandar
    Ou, Jeffrey
    Pak, Christine M.
    Patel, Ronak Y.
    Punj, Sumit
    Richards, Carolyn Sue
    Salama, Joseph
    Strande, Natasha T.
    Yang, Yaping
    Plon, Sharon E.
    Biesecker, Leslie G.
    Rehm, Heidi L.
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2016, 98 (06) : 1067 - 1076
  • [9] [Anonymous], CIRCULATION S4
  • [10] Gene mutations in apical hypertrophic cardiomyopathy
    Arad, M
    Penas-Lado, M
    Monserrat, L
    Maron, BJ
    Sherrid, M
    Ho, CY
    Barr, S
    Karim, A
    Olson, TM
    Kamisago, M
    Seidman, JG
    Seidman, CE
    [J]. CIRCULATION, 2005, 112 (18) : 2805 - 2811